HOOKIPA Pharma, identified by the ticker HOOK, has announced plans to divest its key immuno-oncology assets to NeoTrail Therapeutics. This transaction includes primarily the HB-200 and HB-700 development programs. Although the financial details of this sale have not been disclosed, the agreement was officially signed on January 28, 2026. The deal is anticipated to be finalized in the second quarter of 2026, contingent upon the fulfillment of customary closing conditions.
https://www.gurufocus.com/news/8577709/hookipa-pharma-hook-divests-key-immunooncology-assets
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.